Search

Your search keyword '"Laharie, David"' showing total 898 results
Start Over Author "Laharie, David"
898 results on '"Laharie, David"'

201. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

Author

Sandborn, William J., Ghosh, Subrata, Panes, Julian, Vranic, Ivana, Wang, Wenjin, Niezychowski, Wojciech, Vermeire, Severine A.R.A., Dewit, Olivier, Peeters, Harald, Stehlik, Jiri, Vanasek, Tomas, Laharie, David, Colombel, Jean Frederic, Bigard, Marc-André, Varga, Marta, Zeher, Margit, Novak, Janos, Hunyady, Bela, Salamon, Agnes, Racz, Istvan, Gionchetti, Paolo, Kohn, Anna, Prantera, Cosimo, Stokkers, P. C.F., Slomka, Maria, Paradowski, Leszek, Arlukowicz, Tomasz, Kuzela, Ladislav, Baricky, Boris, Hlavaty, Tibor, Vera, Maria Isabel, Panes, Julian, Guardiola, Jordi, Probert, Christopher, Shaffer, Jonathan Lionel, Fleisher, Mark, Pruitt, Ronald Edward, Sandborn, William J., Goff, John Sawyer, Weber, John, Bell, Raymond Lloyd, Zwick, Andrew Harrison, Gutierrez, Alexandra, Levine, Robert H., Hanauer, Stephen Brett, Lavelle, Lori Ann, Kottoor, Ravindranath K., Dryden, Gerald Wayne, Jr., Hardi, Robert, Glorioso, David Vaughn, Swaroop, Prabhakar, Lee, Scott D., Patrick, Teressa Joan, Scheinert, Sheldon, Sninsky, Charles A., Katz, Seymour, Noar, Mark D., Gaspari, Michael Marion, Gordon, Glenn L., Dalton, Thomas A., Homoky, Douglas Edward, Kilgore, William Ransom, III, Levien, Joel A., Schneider, Herbert R., Moola, Suleman Abdul, Kruger, Frederik Cornelius, Wright, John P., and Aboo, Nazimuddin

Published
2014
Full Text
View/download PDF

206. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

Author

Ungaro, Ryan C., Yzet, Clara, peter bossuyt, Baert, Filip J., Vanasek, Tomas, D Haens, Geert R., Joustra, Vincent W., Panaccione, Remo, Novacek, Gottfried, Armuzzi, Alessandro, Golovchenko, Oleksandr, Olga, Prymak, Goldis, Adrian, Travis, Simon P., Hebuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Grimaud, Jean-Charles, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P., Gomollon, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellstrom, Per M., Halfvarson, Jonas, and Colombel, Jean Frederic

Abstract

Background We aimed to describe the long-term impact of achieving endoscopic and deep remission among participants in the effect of tight control management on CD (CALM) trial. Methods We analysed medical records from patients with follow-up data since end of CALM. Patients were stratified by outcomes in CALM at 1 year: clinical remission (Crohn’s disease activity index, CDAI Results One hundred twenty-two patients with median age 29 years (IQR 22.5–37) and median disease duration 0.2 years (IQR 0.1–0.8) were included. Median follow-up time from end of CALM was 3.02 years (range 0.05–6.26 years). Fifty per cent were randomised to the tight control arm. There were no significant differences in baseline characteristics in patients with follow-up data and those lost to follow-up with the exception of a slightly higher CDEIS score in patients lost to follow-up (14.6 vs. 12.9, p = 0.04). Thirty-four patients (27.9%) had a major adverse outcome during follow-up. Patients in clinical remission at 1 year did not have significantly lower rates of the composite endpoint (log-rank p = 0.15). Patients in endoscopic and deep remission at the end of CALM were significantly less likely to have a major adverse event over time (Figures 1 and 2). After adjusting for age, disease duration, prior surgery, prior stricture, and randomisation arm, endoscopic remission (aHR 0.44, 95% CI 0.20–0.96, p = 0.038) and deep remission (aHR 0.25, 95% CI 0.09–0.72, p = 0.01) were significantly associated with lower risk of major adverse events. Conclusions Early CD patients who achieve endoscopic or deep remission after 1 year of intensive treatment are less likely to have disease progression over a median of 3 years.

Published
2019

207. The variation of faecal calprotectin level within the first months after bowel resection is predictive of endoscopic postoperative recurrence in patients with Crohn's disease

Author

Boube, Mathilde, Laharie, David, Nancey, Stéphane, Hébuterne, Xavier, Fumery, Mathurin, Pariente, Benjamin, Roblin, Xavier, Peyrin-Biroulet, Laurent, Reymond, Maud, Allimant, Christophe, Minet-Quinard, Régine, Pereira, Bruno, Bommelaer, Gilles, Buisson, Anthony, Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, CHU Bordeaux [Bordeaux], Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Hôpital l'Archet, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Biochimie, CHU Clermont-Ferrand, Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), European Crohn’s and Colitis Organisation, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

208. Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease

Author

Fumery, Mathurin, Peyrin-Biroulet, Laurent, Nancey, Stéphane, Altwegg, Romain, Veyrard, Pauline, Bouguen, Guillaume, Viennot, Stéphanie, Poullenot, Florian, Filippi, Jérôme, Buisson, Anthony, Bozon, Anne, Gilletta, Cyrielle, Brazier, Franck, Pouillon, Lieven, Flourié, Bernard, Boivineau, Lucile, Siproudhis, Laurent, Laharie, David, Roblin, Xavier, Treton, Xavier, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], CHU Pontchaillou [Rennes], Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Nice (CHU Nice), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Service d'Hépatologie Gastro-entérologie [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU de Bordeaux Pellegrin [Bordeaux], European Crohn’s and Colitis Organisation, DESSAIVRE, Louise, Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], and Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Abstract

International audience

Published
2019

209. Prise en charge des fistules ano-périnéales au cours de la maladie de Crohn, actualisation 2021 du consensus de la Société Nationale Française de Colo-Proctologie.

Author

Bouchard, Dominique, Pigot, François, Siproudhis, Laurent, de Parades, Vincent, Abramowitz, Laurent, Staumont, Ghislain, Laharie, David, Bouguen, Guillaume, Peyrin-Biroulet, Laurent, Roblin, Xavier, Pariente, Benjamin, Cotte, Eddy, Zerbib, Philippe, and Panis, Yves

Abstract

Résumé: Les cibles des lésions anales méritent d'être clarifiées parce qu'elles ne peuvent être évaluées avec les mêmes outils que la maladie luminale. Dans l'état actuel de la pratique ou des publications scientifiques, l'évaluation repose sur une approche pragmatique (nécessité d'une (ré-)intervention chirurgicale), sur des scores mixtes anciens (Perineal Disease Activity Index), des caractéristiques cliniques sommaires (fistule ouverte ou fermée) ou des scores radiologiques plus subtils mais non validés. Les stratégies thérapeutiques médicochirurgicales récentes ont été définies sans que l'on connaisse la quantité d'effet des biothérapies seules ou en combothérapie, et le résultat des stratégies innovantes telles que l'injection in situ de cellules souches. Cette dernière technique bénéficie d'une autorisation de mise sur le marché (AMM) et d'un remboursement alors qu'on ne dispose que d'un nombre encore restreint d'études. Trois catégories de cibles thérapeutiques proposées ont été retenues dans le consensus : symptômes, données d'examen clinique et données IRM. De façon consensuelle, le temps nécessaire pour évaluer cliniquement l'efficacité du traitement était de six mois. La réponse IRM devait comprendre l'absence de collection de 10 mm ou plus à six mois et une diminution franche ou une disparition de l'hyper-intensité du trajet principal à douze mois. The targets of anal lesions need to be clarified because they cannot be assessed with the same tools as luminal disease. In the current state of practice or scientific publications, evaluation is based on a pragmatic approach (need for surgical (re-)intervention), on old mixed scores (Perineal Disease Activity Index), summary clinical characteristics (open or closed fistula) or more subtle but unvalidated radiological scores. Recent medical-surgical treatment strategies have been defined without knowing the effect of biotherapies alone or in combination, and the outcome of innovative strategies such as in situ stem cell injection. The latter technique has a marketing authorisation and reimbursement, although only a limited number of studies are available. Three categories of proposed therapeutic targets were retained in the consensus: symptoms, clinical examination data and MRI data. The consensus was that the time to clinically assess treatment efficacy was 6 months. MRI response should include the absence of a collection of 10 mm or more at 6 months and a clear reduction or disappearance of the hyperintensity of the main pathway at 12 months. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

211. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.

Author

Uzzan, Mathieu, Bresteau, Clément, Laharie, David, Stefanescu, Carmen, Bellanger, Christophe, Carbonnel, Franck, Serrero, Mélanie, Viennot, Stéphanie, Nachury, Maria, Amiot, Aurélien, Altwegg, Romain, Picon, Laurence, Nahon, Stéphane, Vuitton, Lucine, Ah Soune, Philippe, Kirchgesner, Julien, Peyrin‐Biroulet, Laurent, Bouhnik, Yoram, Treton, Xavier, and Meyer, Antoine

Subjects
ULCERATIVE colitis, SALVAGE therapy, HERPES zoster, DISEASE remission, STEROID drugs, INFLAMMATORY bowel diseases
Abstract

Summary: Background: Up to 25% of patients with ulcerative colitis (UC) will require hospitalization for severe flare. In patients hospitalised for severe flare, who previously experienced multiple drug failures, including steroids and anti‐TNF agents, new quick‐acting medical options are needed. Tofacitinib is effective in refractory UC and has a rapid onset of action. Aim: To evaluate effectiveness and safety of tofacitinib as rescue therapy in patients hospitalised for UC flare. Methods: We conducted an observational and multicentre study with both retrospective and prospective collections in 14 GETAID centres. The primary objective was to assess the survival without colectomy following tofacitinib initiation in patients hospitalised for a UC flare. We determined rates of clinical response, clinical remission, and steroid‐free clinical remission at week 6 and week 14 and safety. Results: Fifty‐five patients were included (49 with prior infliximab failure and 19 previously exposed to ciclosporin). With a median follow‐up of 6.5 months (interquartile range [IQR] [3‐12.3]), rate of colectomy‐free survival was estimated at 78.9% (95 CI [68.5‐90.9]) and 73.6% (95 CI [61.9‐87.3]) at 3 and 6 months, respectively. Rates of clinical response, clinical remission and steroid‐free clinical remission were 60%, 45.5% and 37.5% at week 6 and 41.8%, 34.5% and 32.7% at week 14. Regarding safety, no death was observed, three patients withdrew tofacitinib due to adverse events. Two herpes zoster infections occurred in patients aged over 60 years old. No venous thrombotic or major adverse cardiovascular events occurred. Conclusion: Tofacitinib appears as a promising option in patients hospitalised with a UC flare but needs further validation in controlled trials. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

212. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

Author

D'Haens, Geert, Vermeire, Severine, Lambrecht, Guy, Baert, Filip, Bossuyt, Peter, Pariente, Benjamin, Buisson, Anthony, Bouhnik, Yoram, Filippi, Jérôme, vander Woude, Janneke, Van Hootegem, Philippe, Moreau, Jacques, Louis, Edouard, Franchimont, Denis, De Vos, Martine, Mana, Fazia, Peyrin-Biroulet, Laurent, Brixi, Hedia, Allez, Matthieu, Caenepeel, Philip, Aubourg, Alexandre, Oldenburg, Bas, Pierik, Marieke, Gils, Ann, Chevret, Sylvie, Laharie, David, Détré, Patricia, Bertin, Marie Jo, Williams, Sabrina, and GETAID

Subjects
Therapeutic Drug Monitoring, Gastroenterology, Crohn's Disease, Mucosal Healing, Infliximab
Abstract

Background & Aims: A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We performed a prospective, randomized trial to determine whether therapeutic drug monitoring (TDM) to maintain serum levels of infliximab above 3 μg/mL produced higher rates of clinical and endoscopic remission than adapting dose based only on symptoms. Methods: We performed a double-blind trial in which 122 biologic-naïve adult patients with active CD (71 female, median age 29.8 years) received induction treatment with infliximab in combination with an immunosuppressant, from July 2012 through September 2015 at 27 centers in Europe. At week 14 of treatment, patients were randomly assigned (1:1:1) to 3 infliximab maintenance groups: dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (dose intensification strategy [DIS]1 group); dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group); dose increase to 10 mg/kg based on clinical symptoms alone (controls). Patients’ CD activity index scores, levels of C-reactive protein, fecal levels of calprotectin, and serum concentrations of infliximab were determined at baseline and at weeks 2, 4, 6, 12, and 14 of treatment, and then every 4 weeks thereafter until week 54. The primary endpoint was sustained corticosteroid-free clinical remission (CD activity index

Published
2018

218. Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study

Author

Caron, Benedicte, primary, Peyrin-Biroulet, Laurent, additional, Pariente, Benjamin, additional, Bouhnik, Yoram, additional, Seksik, Philippe, additional, Bouguen, Guillaume, additional, Caillo, Ludovic, additional, Laharie, David, additional, Carbonnel, Franck, additional, Altwegg, Romain, additional, Reenaers, Catherine, additional, Serrero, Melanie, additional, Trang-Poisson, Caroline, additional, Nancey, Stephane, additional, Filippi, Jerome, additional, Abitbol, Vered, additional, Savoye, Guillaume, additional, Vuitton, Lucine, additional, Viennot, Stephanie, additional, Fumery, Mathurin, additional, Reymond, Maud, additional, Bronowicki, Jean-Pierre, additional, Reimund, Jean-Marie, additional, and Amiot, Aurelien, additional

Published
2019
Full Text
View/download PDF

219. Reply

Author

Laharie, David, primary and Pellet, Gauthier, additional

Published
2019
Full Text
View/download PDF

221. Tu1748 – Oral Curcumin is Not More Effective Than Placebo to Prevent Endoscopic Postoperative Recurrence in Patients with Crohn's Disease Treated with Concomitant Thiopurines: Results from a Randomized Controlled Trial

Author

Bommelaer, Gilles, primary, Laharie, David, additional, Nancey, Stephane, additional, Hebuterne, Xavier, additional, Roblin, Xavier, additional, Nachury, Maria, additional, Peyrin-Biroulet, Laurent, additional, Fumery, Mathurin, additional, Pereira, Bruno, additional, Goutte, Marion, additional, and Buisson, Anthony, additional

Published
2019
Full Text
View/download PDF

222. Mo1816 – Prediction of Endoscopic Activity in Patients with Crohn’s Disease – Systematic Review and External Validation of Published Prediction Models

Author

Brand, Eelco C., primary, Elias, Sjoerd G., additional, Minderhoud, Itta M., additional, van der Veen, Julius J., additional, Baert, Filip J., additional, Laharie, David, additional, Bossuyt, Peter, additional, Bouhnik, Yoram, additional, Buisson, Anthony, additional, Lambrecht, Guy, additional, Louis, Edouard, additional, Pariente, Benjamin, additional, Pierik, Marie, additional, Van Der Woude, Christien Janneke, additional, D’Haens, Geert R., additional, Vermeire, Severine, additional, and Oldenburg, Bas, additional

Published
2019
Full Text
View/download PDF

223. 365 – Efficacy and Safety of Infliximab Retreatment in Luminal Crohn's Disease: A Multicentre, Prospective, Observational Cohort (Regain) Study

Author

Boschetti, Gilles, primary, Pariente, Benjamin, additional, Laharie, David, additional, Roblin, Xavier, additional, Gilletta, Cyrielle, additional, Aubourg, Alexandre, additional, Bourreille, Arnaud, additional, Zallot, Camille, additional, Hebuterne, Xavier, additional, Buisson, Anthony, additional, Grimaud, Jean-charles, additional, Bouhnik, Yoram, additional, Allez, Matthieu, additional, Altwegg, Romain, additional, Viennot, Stephanie, additional, Vuitton, Lucine, additional, Carbonnel, Franck, additional, Nachury, Maria, additional, Paul, Stephane, additional, lambert, jerome, additional, and Peyrin-Biroulet, Laurent, additional

Published
2019
Full Text
View/download PDF

224. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm

Author

Ungaro, Ryan C., primary, Yzet, Clara, additional, Bossuyt, Peter, additional, Baert, Filip J., additional, Vanasek, Tomas, additional, D'Haens, Geert R., additional, Joustra, Vincent W., additional, Panaccione, Remo, additional, Novacek, Gottfried, additional, Armuzzi, Alessandro, additional, Golovchenko, Oleksandr, additional, Olga, Prymak, additional, Goldis, Adrian, additional, Travis, Simon P., additional, Hebuterne, Xavier, additional, Ferrante, Marc, additional, Rogler, Gerhard, additional, Fumery, Mathurin, additional, Danese, Silvio, additional, Rydzewska, Grazyna, additional, Pariente, Benjamin, additional, Hertervig, Erik, additional, Stanciu, Carol, additional, Grimaud, Jean-charles, additional, Diculescu, Mircea, additional, Peyrin-Biroulet, Laurent, additional, Laharie, David, additional, Wright, John P, additional, Gomollon, Fernando, additional, Gubonina, Irina, additional, Schreiber, Stefan, additional, Motoya, Satoshi, additional, Hellström, Per M., additional, Halfvarson, Jonas, additional, and Colombel, Jean Frederic, additional

Published
2019
Full Text
View/download PDF

225. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

Author

MS MDL 1, Infection & Immunity, D'Haens, Geert, Vermeire, Severine, Lambrecht, Guy, Baert, Filip, Bossuyt, Peter, Pariente, Benjamin, Buisson, Anthony, Bouhnik, Yoram, Filippi, Jérôme, vander Woude, Janneke, Van Hootegem, Philippe, Moreau, Jacques, Louis, Edouard, Franchimont, Denis, De Vos, Martine, Mana, Fazia, Peyrin-Biroulet, Laurent, Brixi, Hedia, Allez, Matthieu, Caenepeel, Philip, Aubourg, Alexandre, Oldenburg, Bas, Pierik, Marieke, Gils, Ann, Chevret, Sylvie, Laharie, David, Détré, Patricia, Bertin, Marie Jo, Williams, Sabrina, GETAID, MS MDL 1, Infection & Immunity, D'Haens, Geert, Vermeire, Severine, Lambrecht, Guy, Baert, Filip, Bossuyt, Peter, Pariente, Benjamin, Buisson, Anthony, Bouhnik, Yoram, Filippi, Jérôme, vander Woude, Janneke, Van Hootegem, Philippe, Moreau, Jacques, Louis, Edouard, Franchimont, Denis, De Vos, Martine, Mana, Fazia, Peyrin-Biroulet, Laurent, Brixi, Hedia, Allez, Matthieu, Caenepeel, Philip, Aubourg, Alexandre, Oldenburg, Bas, Pierik, Marieke, Gils, Ann, Chevret, Sylvie, Laharie, David, Détré, Patricia, Bertin, Marie Jo, Williams, Sabrina, and GETAID

Published
2018

226. Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn's Disease: A Multicentre Study.

Author

Fumery, Mathurin, Peyrin-Biroulet, Laurent, Nancey, Stephane, Altwegg, Romain, Gilletta, Cyrielle, Veyrard, Pauline, Bouguen, Guillaume, Viennot, Stephanie, Poullenot, Florian, Filippi, Jerome, Buisson, Anthony, Bozon, Anne, Brazier, Franck, Pouillon, Lieven, Flourie, Bernard, Boivineau, Lucile, Siproudhis, Laurent, Laharie, David, Roblin, Xavier, and Diouf, Momar

Abstract

Background The approved maintenance regimens for ustekinumab in Crohn's disease [CD] are 90 mg every 8 or 12 weeks. Some patients will respond partially to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections. Methods All patients with active CD, as defined by Harvey–Bradshaw score ≥ 4 and one objective sign of inflammation [C-reactive protein > 5 mg/L and/or faecal calprotectin > 250 µg/g and/or radiological and/or endoscopic evidence of disease activity] who required ustekinumab dose escalation to 90 mg every 4 weeks for loss of response or incomplete response to ustekinumab 90 mg every 8 weeks were included in this retrospective multicentre cohort study. Results One hundred patients, with a median age of 35 years [interquartile range, 28–49] and median disease duration of 12 [7–20] years were included. Dose intensification was performed after a median of 5.0 [2.8–9.0] months of ustekinumab treatment and was associated with corticosteroids and immunosuppressants in respectively 29% and 27% of cases. Short-term clinical response and clinical remission were observed in respectively 61% and 31% after a median of 2.4 [1.3–3.0] months. After a median follow-up of 8.2 [5.6–12.4] months, 61% of patients were still treated with ustekinumab, and 26% were in steroid-free clinical remission. Among the 39 patients with colonoscopy during follow-up, 14 achieved endoscopic remission [no ulcers]. At the end of follow-up, 27% of patients were hospitalized, and 19% underwent intestinal resection surgery. Adverse events were reported in 12% of patients, including five serious adverse events. Conclusion In this multicentre study, two-thirds of patients recaptured response following treatment intensification with ustekinumab 90 mg every 4 weeks. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

228. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease.

Author

Dreesen, Erwin, Berends, Sophie, Laharie, David, D'Haens, Geert, Vermeire, Séverine, Gils, Ann, and Mathôt, Ron

Subjects
CROHN'S disease, CALPROTECTIN, INFLAMMATORY bowel diseases, INFLIXIMAB, PLATELET count, C-reactive protein, DRUG monitoring
Abstract

Aims: Evidence for the benefits of pharmacokinetic (PK) and pharmacodynamic (PD) monitoring of infliximab in patients with Crohn's disease (CD) remains scarce. We aimed to develop a population (pop)PK/PD model to characterise the infliximab dose–exposure–biomarker–response (faecal calprotectin [fCal] and endoscopic remission [ER]) relationship. Methods: Data were obtained from 116 patients with CD in a phase 4 dose‐escalation study. Three sequential models were developed: a 2‐compartment popPK model linking infliximab dose to exposure; an indirect response popPK/PD model describing the inhibitory effect of infliximab exposure on fCal; and a first‐order Markov popPD model linking fCal to transitions between states of ER, no ER and dropout. Results: Infliximab clearance increased with increasing fCal, decreasing albumin, increasing CD activity index and presence of anti‐drug antibodies. Baseline fCal increased with increasing C‐reactive protein and decreasing platelet count. Lower fCal increased the probability of attaining ER and decreased the probability of losing ER. Probability of dropping out given an earlier state of absence of ER increased with time. Large interpatient PK and PD variability resulted in a flat dose–response curve. Predicted fraction of patients achieving ER was 45% [30–61] (median [interquartile range], n = 50 000) when on 5 mg/kg infliximab (~46% observed in data). Simulations with 10 mg/kg induction doses predicted an increase to 48% [32–63]. This minor benefit at the population level argues against systematic 10 mg/kg induction dosing in all patients. Conclusion: Model‐informed infliximab dose optimisation towards a predefined fCal concentration (while accounting for PK and PD variability) may improve effectiveness of infliximab therapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

229. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease

Author

Buisson, Anthony, Nancey, Stéphane, Manlay, Luc, Rubin, David T, Hebuterne, Xavier, Pariente, Benjamin, Fumery, Mathurin, Laharie, David, Roblin, Xavier, Bommelaer, Gilles, Pereira, Bruno, Peyrin‐Biroulet, Laurent, and Vuitton, Lucine

Abstract

Preventing postoperative recurrence (POR) is a major concern in Crohn's disease (CD). While azathioprine is an option, no data is available on ustekinumab efficacy in this situation. We compared the effectiveness of ustekinumab versus azathioprine in preventing endoscopic POR in CD. We retrospectively collected data from all consecutive CD patients treated with ustekinumab after intestinal resection in 9 centers. The control group (azathioprine alone) was composed of patients who participated in a randomized controlled trial conducted in the same centers comparing azathioprine alone or in combination with curcumin. Propensity score analyses (inversed probability of treatment weighting = IPTW) were applied to compare the two groups. The primary endpoint was endoscopic POR (Rutgeerts' index ≥ i2) at 6 months. Overall, 32 patients were included in the ustekinumab group and 31 in the azathioprine group. The propensity score analysis was adjusted on the main risk factors (smoking, fistulizing phenotype, prior bowel resection, resection length >30 cm and ≥2 biologics before surgery) and thiopurines or ustekinumab exposure prior to surgery making the two arms comparable (∣d∣ < 0.2). After IPTW, the rate of endoscopic POR at 6 months was lower in patients treated with ustekinumab compared to azathioprine (28.0% vs. 54.5%, p= 0.029). After IPTW, the rates of i2b‐endoscopic POR (Rutgeerts' index ≥ i2b) and severe endoscopic POR (Rutgeerts' index ≥ i3) were 20.8% versus 42.5% (p= 0.066) and 16.9% versus 27.9% (p= 0.24), in the ustekinumab and azathioprine groups, respectively. Ustekinumab seemed to be more effective than azathioprine in preventing POR in this cohort of CD patients.

Published
2021
Full Text
View/download PDF

230. Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study.

Author

Lambin, Thomas, Amiot, Aurélien, Stefanescu, Carmen, Gornet, Jean-Marc, Seksik, Philippe, Laharie, David, Reenaers, Catherine, Bourreille, Arnaud, Cadiot, Guillaume, Carbonnel, Franck, Dib, Nina, Fumery, Mathurin, Gilletta de St Joseph, Cyrielle, Filippi, Jérôme, Viennot, Stéphanie, Plastaras, Laurianne, Coffin, Benoit, Serrero, Mélanie, Nahon, Stéphane, and Pineton de Chambrun, Guillaume

Abstract

There are few data concerning patients with Crohn's disease (CD) complicated by a stricture of the upper gastrointestinal tract (UGT). We evaluated the outcome and management of CD patients complicated by a stricture of the UGT. We performed a retrospective multicenter study including all CD patients with a non-passable symptomatic UGT stricture on endoscopy. Primary outcome measure was surgery-free survival from diagnosis of stricture. Efficacy of medical, endoscopic, and surgical treatments, and identification of predictors of surgery were also evaluated. 60 CD patients with an UGT stricture were included. 60% of the strictures were located in the duodenum. With a median follow-up of 5.5 (IQR: 3.0–12.0) years since stricture diagnosis, surgical-free survival was 75% and 64% at 1 and 5 years, respectively. At the end of the follow up, 27 (45%) patients underwent surgery. 77 endoscopic procedures were performed in 30 patients with an immediate success of 81% and a clinical benefit in 84% of the procedures. In multivariate analysis, anti-TNF treatment initiation was associated with a reduced risk of surgery. CD UGT strictures are mainly located in the duodenum. Medical and endoscopic treatments allow to avoid surgery in half of the patients [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

231. Altered sleep quality is associated with Crohn's disease activity: an actimetry study.

Author

Bazin, Thomas, Micoulaud Franchi, Jean-Arthur, Terras, Nathalie, Taillard, Jacques, Laharie, David, Zerbib, Frank, and Philip, Pierre

Abstract

Background: Sleep is involved in the regulation of inflammation, healing, and digestion. The pathophysiology of Crohn's disease (CD) is unclear, and the role of sleep disturbances has recently been suggested. Objective: The present study investigated a putative association between sleep disturbances and CD activity. Methods: We conducted a prospective observational monocenter translational study, recruiting major CD patients from 2013 to 2015. Disease activity was assessed by the Harvey-Bradshaw index and the CD activity index. Objective sleep quantity and quality were measured by wrist actigraphy over a period of 7 days. The primary objective was to look for an association between wrist actigraphy parameters and CD activity. Results: Thirty-four CD patients, including 14 with active disease and 20 in remission, were included. Sleep efficiency measured by wrist actigraphy was lower in patients with active CD compared to patients in remission. Wake after sleep onset time best predicted CD activity with an AUROC of 0.83. Patients with active CD were more frequently characterized as "poor sleepers" and frequently suffered from excessive daytime sleepiness. Conclusion: Sleep efficiency is lower in patients with active CD than in those in remission. Further studies aimed at better characterizing CD patients' sleep are warranted. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

232. Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update.

Author

Burri, Emanuel, Maillard, Michel H., Schoepfer, Alain M., Seibold, Frank, Van Assche, Gert, Rivière, Pauline, Laharie, David, and Manz, Michael

Subjects
ULCERATIVE colitis, ALGORITHMS, INDIVIDUALIZED medicine, SMALL molecules, MEDICAL protocols
Abstract

Background: Patient care in ulcerative colitis (UC) remains challenging despite an array of established treatment options and emerging new therapies. The management of UC therapy should be guided by the endoscopic extent of inflammation, disease severity, and prognostic factors of poor outcome. Complete remission, defined as durable symptomatic and endoscopic remission without corticosteroid therapy, is the desired treatment goal. Summary: This review focuses on treatment recommendations for different clinical scenarios in moderate-to-severe UC: Active UC of any extent not responding to aminosalicylates, steroid-dependent UC, steroid-refractory UC, immunomodulator-refractory UC, and acute severe UC. Comprehensive treatment algorithms for daily clinical practice were developed based on published guidelines and current literature. Key Messages: While current treatment options including a number of biologicals and small molecules have evolved UC treatment to achieve sustained remission in a majority of patients, upcoming treatment options with different molecular pathways and different modes of actions will further increase the need for personalized medicine. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

233. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.

Author

Martin, Antoine, Nachury, Maria, Peyrin-Biroulet, Laurent, Bouhnik, Yoram, Nancey, Stephane, Bourrier, Anne, Serrero, Melanie, Fumery, Mathurin, Buisson, Anthony, Laharie, David, Gilletta, Cyrielle, Filippi, Jerome, Allez, Matthieu, Bouguen, Guillaume, Roblin, Xavier, Altwegg, Romain, Dib, Nina, Chambrun, Guillaume Pineton de, Savoye, Guillaume, and Carbonnel, Franck

Abstract

Background and Aim It is unclear whether vedolizumab therapy can be discontinued in patients with inflammatory bowel disease [IBD] after achieving steroid-free clinical remission. The aim was to assess the risk of relapse after vedolizumab therapy was discontinued. Methods This was a retrospective observational study, collecting data from 21 tertiary centres affiliated with the GETAID from January 2017 to April 2019. Consecutive patients with IBD, who were in steroid-free clinical remission for at least 3 months and were treated with vedolizumab for at least 6 months, were included at the time of vedolizumab discontinuation. Results A total of 95 patients [58 with Crohn's disease] discontinued vedolizumab after a median duration of therapy of 17.5 [10.6–25.4] months. After a median follow-up period of 11.2 [5.8–17.7] months, 61 [64%] patients experienced disease relapse. The probabilities of relapse-free survival were 83%, 59%, and 36% at 6, 12, and 18 months, respectively. According to the multivariate analysis, a C-reactive protein level less than 5 mg/L at vedolizumab discontinuation (hazard ratio [HR] = 0.56, 95% confidence interval [CI] [0.33–0.95], p = 0.03) and discontinuation due to patients' elective choice (HR = 0.41, 95% CI [0.21–0.80], p = 0.009) were significantly associated with a lower risk of relapse. Re-treatment with vedolizumab was noted in 24 patients and provided steroid-free clinical remission in 71% and 62.5% at Week 14 and after a median follow-up of 11.0 [5.4–13.3] months, respectively, without any infusion reactions. Conclusions In this retrospective study, two-thirds of patients with IBD treated with vedolizumab experienced relapse within the first year after vedolizumab discontinuation. Re-treatment with vedolizumab was effective in two-thirds of patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

234. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease.

Author

Boube, Mathilde, Laharie, David, Nancey, Stéphane, Hebuterne, Xavier, Fumery, Mathurin, Pariente, Benjamin, Roblin, Xavier, Peyrin-biroulet, Laurent, Minet-quinard, Régine, Pereira, Bruno, Bommelaer, Gilles, and Buisson, Anthony

Abstract

Early prediction of postoperative recurrence (POR) remains a major concern in Crohn's disease (CD). To assess serial faecal calprotectin (Fcal) monitoring within the first three months to predict CD endoscopic POR. In a multicenter randomized controlled trial, CD patients received azathioprine 2.5 mg/kg/day with oral curcumin (3 g/day) or placebo. Fcal was measured at baseline, one month (M1) and M3. Endoscopic POR at M6 was defined as Rutgeerts' index ≥ i2b (central reading). Among the 48 patients included, there was no significant difference of median Fcal levels at baseline (p = 0.15), M1 (p = 0.44) and M3 (p = 0.28) between patients with or without endoscopic POR at M6. Fcal kinetics during the first 3 months after surgery was significantly different between the patients with or without POR at M6 (p = 0.021). The median variation between Fcal level at baseline and M3 (ΔFcal M3–M0) was significantly higher in patients with endoscopic POR compared to those without POR (p = 0.01). ΔFcal M3–M0 >+10% demonstrated the best performances to predict endoscopic POR at M6 (AUC=0.73, sensitivity=64.7%[41.1–82.7], specificity=87.5%[68.0–96.3], negative predictive value=77.8%[57.5–91.4] and positive predictive value=78.6%[49.2–95.3]). Fcal variation within the first three months after ileocolonic resection is a promising predictor of early endoscopic POR in CD patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

235. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease.

Author

Brand, Eelco C., Elias, Sjoerd G., Minderhoud, Itta M., van der Veen, Julius J., Baert, Filip J., Laharie, David, Bossuyt, Peter, Bouhnik, Yoram, Buisson, Anthony, Lambrecht, Guy, Louis, Edouard, Pariente, Benjamin, Pierik, Marieke J., van der Woude, C. Janneke, D'Haens, Geert R.A. M., Vermeire, Séverine, and Oldenburg, Bas

Abstract

Endoscopic healing, an important target of treatment for Crohn's disease (CD), requires ileocolonoscopy, which is costly and burdensome. We investigated whether published noninvasive models (based on symptoms and biomarkers) to evaluate CD activity have sufficient accuracy to replace ileocolonoscopy. We performed a systematic review of published noninvasive diagnostic models to evaluate CD activity that used endoscopic features of activity (endoscopic activity) or healing as the reference standard. We externally validated these models for the outcome endoscopic activity (CD endoscopic index of severity scores, ≥3) using data from the a randomized controlled trial investigating tailored treatment with infliximab for active luminal Crohn's disease (TAILORIX) study (346 ileocolonoscopies in 155 patients) and the Utrecht Activity Index (UAI) study (93 ileocolonoscopies in 82 patients). We calculated the area under the receiver operating characteristic curves (AUROCs) for the models using data from these studies, and compared the performance of these models against measurements of fecal calprotectin (FC) and C-reactive protein (CRP). We screened 5303 articles and identified 27 models (from 21 studies) for our analysis. Seven models could be validated externally; in the TAILORIX data set, these models identified patients with endoscopic activity with AUROC values ranging from 0.61 (95% CI, 0.51–0.70) to 0.81 (95% CI, 0.76–0.86). In this data set, the AUROC value for FC concentration was 0.79 (95% CI, 0.74–0.85) and the AUROC value for CRP level was 0.72 (95% CI, 0.66–0.77). The AUROC values for the validation in the UAI data set were similar. In the TAILORIX and/or UAI data set, 4 of the 7 models, as well as the FC and CRP assays, were able to identify patients with endoscopic activity with positive predictive values of 90% or more. Two of the 7 models (but not the FC or CRP values) identified patients without endoscopic activity with a negative predictive value (NPV) of 90% or more, leading to correct prediction of endoscopic healing in 3.2% to 11.3% of all patients. For example, applying the Herranz–Bachiller model (1 of 7 models) at a NPV of 92.1% and a positive predictive value of 91.9% correctly identified 35.7% of all patients in whom ileocolonoscopy could be avoided for expected endoscopic activity or healing but incorrectly identified 3.2% of all patients. Most ileocolonoscopies (66.5% in TAILORIX and 72.6% in the UAI of all ileocolonoscopies) could be avoided correctly based on concentrations of FC of 100 μg/g or less and 250 μg/g or higher. However, using this range of FC concentrations to identify patients who do not require ileocolonoscopy caused 18.7% of all patients in the TAILORIX cohort and 19.8% of all patients in the UAI cohort to be predicted incorrectly to have endoscopic activity or healing. In a systematic review and external validation of noninvasive models to identify patients with endoscopic activity of CD, we found only 2 of 7 models evaluated to have NPVs of 90% or more, however, leading to correctly predicted EH in only a small proportion of patients. Ileocolonoscopy therefore remains the mainstay to evaluate CD mucosal disease activity and healing. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

237. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study.

Author

Amiot, Aurélien, Filippi, Jérôme, Abitbol, Vered, Cadiot, Guillaume, Laharie, David, Serrero, Melanie, Altwegg, Romain, Bouhnik, Yoram, Peyrin‐Biroulet, Laurent, Gilletta, Cyrielle, Roblin, Xavier, Pineton de Chambrun, Guillaume, Vuitton, Lucine, Bourrier, Anne, Nancey, Stephane, Gornet, Jean‐Marc, Nahon, Stephane, Bouguen, Guillaume, Viennot, Stephanie, and Pariente, Benjamin

Subjects
ULCERATIVE colitis, DISEASE remission, PATIENT safety, COHORT analysis, INFLAMMATORY bowel diseases, ADVERSE health care events
Abstract

Summary: Background: Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate‐to‐severe ulcerative colitis (UC), but few real‐world data are currently available. Aim: To assess short‐term effectiveness and safety of ustekinumab in patients with UC. Methods: From January to September 2019, all patients with UC treated with ustekinumab in 20 French GETAID centres were retrospectively included. The primary outcome was steroid‐free clinical remission (partial Mayo Clinic score ≤2) at weeks 12‐16 without a rectal bleeding subscore >1. Results: Among the 103 patients included, 70% had been previously exposed to ≥2 anti‐TNF agents and 85% to vedolizumab. At weeks 12‐16, steroid‐free clinical remission and clinical remission rates were 35.0% and 39.8% respectively; the absence of rectal bleeding with normal stool frequency was noted in 19.4% of patients. Two patients discontinued ustekinumab before the week 12‐16 visit and underwent surgery. In multivariable analysis, a partial Mayo Clinic score >6 at inclusion (18.6% vs 46.7%, P = 0.003) and a history of both exposure to anti‐TNF and vedolizumab therapies (27.3% vs 80.0%, P = 0.001) were negatively associated with steroid‐free clinical remission at weeks 12‐16. Adverse events occurred in 7.8% of patients and serious adverse events in 3.9% of patients. Conclusion: In a cohort of highly refractory patients with UC with multiple prior drug failures, ustekinumab provided steroid‐free clinical remission in one‐third of cases at weeks 12‐16. Clinical severity and previous use of anti‐TNF and vedolizumab therapies were associated with ustekinumab failure at weeks 12‐16. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

238. Prise en charge des maladies inflammatoires chroniques de l'intestin à l'heure de l'épidémie COVID-19.

Author

Amiot, Aurélien and Laharie, David

Abstract

Résumé: À l'heure où la pandémie liée au SARS-CoV-2 fait rage, la question de la prise en charge des patients atteints de maladie inflammatoire chronique de l'intestin se pose du fait de l'emploi d'agents immunomodulateurs. Éviter une rechute potentiellement grave de la maladie digestive et ne pas faire courir de risque accru d'infection par le SARS-CoV-2, ces objectifs doivent être conciliés au cas par cas. Whereas SARS-CoV-2 outbreak is still rising, the appropriate management of patients with inflammatory bowel disease is challenging. On the one hand, there is a risk of relapse if treatment are discontinued. On the other hand, there may be an increased infectious risk if treatment are continued. That dilemna should be resolved on a case-by-case basis. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

239. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.

Author

Sparrow, Miles P, Papamichael, Konstantinos, Ward, Mark G, Riviere, Pauline, Laharie, David, Paul, Stephane, and Roblin, Xavier

Abstract

Biologic therapies have revolutionized the management of inflammatory bowel disease [IBD], but primary and secondary non-responses occur in a significant proportion of patients. Therapeutic drug monitoring [TDM] now has an established role in the treatment algorithm for managing secondary loss of response to anti-tumour necrosis factor [anti-TNF] agents during maintenance therapy. Data to support the use of TDM in the management of secondary loss of response to vedolizumab and ustekinumab are emerging. The potential to prevent primary non-response to biologic agents during induction is of equal, and potentially greater, clinical importance. Again, most data supporting the use of 'proactive' TDM during induction pertains to the use of anti-TNF agents, but signals of efficacy for the use of TDM during induction with other biologic classes are now appearing. This review aims to summarize data on the use of TDM during induction to prevent pharmacokinetic primary non-response to all three classes of biologic therapy currently available for the treatment of IBD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

240. Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.

Author

Poullenot, Florian, Ollivier, Julien, Rivière, Pauline, Sauvaget, Lucie, Berroneau, Aude, Djabarouti, Sarah, Xuereb, Fabien, Zerbib, Frank, Breilh, Dominique, and Laharie, David

Abstract

According to infliximab (IFX) license in Crohn's disease (CD), infusion doses are based on patient's body-weight. Dose banding providing standardized doses (SD) has been implemented in parenteral chemotherapy in order to optimize aseptic unit capacity and reduce drug expenditure, duration of hospital stay and costs without decreasing efficacy. The first part was a single-center retrospective analysis of consecutive CD patients receiving IFX maintenance therapy to determine standardized doses covering more than 50% of infusions. The second part was a prospective cohort study assessing the impact of SD compared to body-weight doses (BWD) on admission duration and costs. Six IFX SD covering more than 90% of infusion doses were implemented for dose banding. According to the Monte-Carlo simulation, there was no significant difference between IFX SD and BWD maintenance regimens. When assessed prospectively in 116 patients (75 patients treated with SD and 41 with BWD) corresponding to 128 infusions, hospitalization duration was shortened by 70 min per patient (p < 0.001). According to a pharmacokinetic model, IFX SD has a pharmacokinetic profile close to BWD and is associated with reduced length of hospitalization in a cohort of patients with CD. IFX SD implementation could optimize infusion units functioning and, save time and costs without decreasing efficacy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

241. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.

Author

Lair-Mehiri, Loriane, Stefanescu, Carmen, Vaysse, Thibaut, Laharie, David, Roblin, Xavier, Rosa, Isabelle, Treton, Xavier, Abitbol, Vered, Amiot, Aurélien, Bouguen, Guillaume, Dib, Nina, Fumery, Mathurin, Pariente, Benjamin, Carbonnel, Franck, Peyrin-Biroulet, Laurent, Simon, Marion, Viennot, Stéphanie, and Bouhnik, Yoram

Abstract

Phase III trials demonstrated effectiveness of tofacitinib, an oral Janus kinase inhibitor, to induce and maintain remission in patients with moderate-to-severe active ulcerative colitis (UC). We report the real-world effectiveness and safety of tofacitinib in patients with UC in France. From February 2017 to December 2018, we performed a national French cohort study, which included all consecutive patients with an active UC refractory to anti-TNF and vedolizumab, who received tofacitinib. Outcomes were survival without colectomy, survival without tofacitinib discontinuation and steroid-free clinical remission at weeks 14, 24 and 48. Thirty-eight patients were included, with a median follow-up of 41.5 (18.5–56.8) weeks. Survival without colectomy was 77% [95% confidence interval (95%CI): 59.3–87.9] at week 24 and 70% (95%CI: 50.9–82.8) at week 48. Survival without treatment discontinuation was 70% (95%CI: 52.6–82.3) at week 24. Steroid-free clinical remission was observed in 13 (34%) patients at week 48. Adverse events occurred in 14 (37%) patients, including 6 severe adverse events and three herpes zoster infections. In a highly refractory UC population, one third of patients treated with tofacitinib achieved steroid-free clinical remission at week 14 and 70% of patients avoided colectomy at one year, with an acceptable safety profile. These data confirm tofacitinib effectiveness in UC, especially after multiple biologic failures. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

242. Reply

Author

D’Haens, Geert, primary, Vermeire, Severine, additional, and Laharie, David, additional

Published
2018
Full Text
View/download PDF

243. Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

Author

Le Baut, Guillaume, primary, Peyrin-Biroulet, Laurent, additional, Bouguen, Guillaume, additional, Gornet, Jean-Marc, additional, Stefanescu, Carmen, additional, Amiot, Aurélien, additional, Laharie, David, additional, Altwegg, Romain, additional, Fumery, Mathurin, additional, Trang, Caroline, additional, Vuitton, Lucine, additional, Simon, Marion, additional, Gilletta de Saint Joseph, Cyrielle, additional, Nahon, Stéphane, additional, Caillo, Ludovic, additional, Del Tedesco, Emilie, additional, Plastaras, Laurianne, additional, Aubourg, Alexandre, additional, Pineton de Chambrun, Guillaume, additional, Seksik, Philippe, additional, and Viennot, Stéphanie, additional

Published
2018
Full Text
View/download PDF

244. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series

Author

Altwegg, Romain, primary, Combes, Roman, additional, Laharie, David, additional, De Ledinghen, Victor, additional, Radenne, Sylvie, additional, Conti, Filomena, additional, Chazouilleres, Olivier, additional, Duvoux, Christophe, additional, Dumortier, Jérôme, additional, Leroy, Vincent, additional, Treton, Xavier, additional, Durand, François, additional, Dharancy, Sébastien, additional, Nachury, Maria, additional, Goutorbe, Félix, additional, Lamblin, Géraldine, additional, Boivineau, Lucile, additional, Peyrin-Biroulet, Laurent, additional, and Pageaux, Georges-Philippe, additional

Published
2018
Full Text
View/download PDF

245. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

Author

Beaugerie, Laurent, primary, Carrat, Fabrice, additional, Nahon, Stéphane, additional, Zeitoun, Jean-David, additional, Sabaté, Jean-Marc, additional, Peyrin-Biroulet, Laurent, additional, Colombel, Jean-Frédéric, additional, Allez, Matthieu, additional, Fléjou, Jean-François, additional, Kirchgesner, Julien, additional, Svrcek, Magali, additional, Cosnes, Jacques, additional, Gendre, Jean-Pierre, additional, Lémann, Marc, additional, Hébuterne, Xavier, additional, Cortot, Antoine, additional, Bouhnik, Yoram, additional, Laharie, David, additional, Dupas, Jean Louis, additional, Flourié, Bernard, additional, Lerebours, Eric, additional, Beaugerie, Laurent, additional, Messing, Bernard, additional, Cadiot, Guillaume, additional, Marteau, Philippe, additional, Soulé, Jean-Claude, additional, Gornet, Jean-Marc, additional, Veyrac, Michel, additional, Duclos, Bernard, additional, Beau, Philippe, additional, Bourreille, Arnaud, additional, Baumer, Philippe, additional, Carbonnel, Franck, additional, Heresbach, Denis, additional, Metman, Etienne-Henry, additional, Florent, Christian, additional, Blain, Antoine, additional, Faucheron, Jean-Luc, additional, Bonaz, Bruno, additional, Roblin, Xavier, additional, Potier, Pascal, additional, Boehm, Christian, additional, Kurtz, Thierry, additional, Lamouliatte, Hervé, additional, Nion-Larmurier, Isabelle, additional, Delchier, Jean-Charles, additional, Chaussade, Stanislas, additional, Weiss, Anne Marie, additional, Cézard, Jean Pierre, additional, Siproudhis, Laurent, additional, Sondag, Daniel, additional, Jian, Raymond, additional, Souquet, Jean-Christophe, additional, Bord, Pierre, additional, Coffin, Benoit, additional, D’almagne, Hélène, additional, Delasalle, Patrick, additional, Fournier, Régis, additional, Cavicchi, Maryan, additional, Souffran, Marc-Henry, additional, Vandromme, Luc, additional, Guedon, Claire, additional, Seksik, Philippe, additional, Michiels, Christophe, additional, Renard, Pascal, additional, Rogier, Patrice, additional, Gouilloud, Sylvie, additional, Rotenberg, André, additional, Savoye, Guillaume, additional, Thevenin, Alain, additional, Mallet, Laurent, additional, Brazier, Franck, additional, Jean, Francois, additional, Justum, Anne-Marie, additional, Latrive, Jean-Paul, additional, Gerbal, Jean-Luc, additional, Pierrugues, Robert, additional, Chardonnal, Gérard, additional, Picon, Laurence, additional, Reix, Nicole, additional, D’aubigny, Nicolas Drouët, additional, Uettwiller, Hervé, additional, Mallet, Anne Courillon, additional, Palacci, Alain, additional, Bensaude, Raoul-Jacques, additional, Bonniaud, Pierre, additional, Empinet, Olivier, additional, Nisard, Andrée, additional, Rudelli, Alain, additional, Tubiana, Bernard, additional, Capelle, Philippe, additional, Dabadie, Alain, additional, Evard, Daniel, additional, Julien, Pierre-Emile, additional, Picon-Coste, Magali, additional, Schneider, Stéphane, additional, Goldfain, Denis, additional, Bellanger, Jérôme, additional, Blondelot, Jean-Pierre, additional, Lamy, Philippe, additional, Lemière, Sébastien, additional, Mockly, Jean Francois, additional, Pellat, Benoit, additional, Gatineau-Sailliant, Gilles, additional, Nalet, Bernard, additional, Nancey, Stéphane, additional, Kusielewicz, Daniel, additional, Loison, Patrick, additional, Popot, Jean-Michel, additional, Merite, François, additional, Roux, Jean-Pol, additional, Afchain, Pauline, additional, Blanquart, Alain, additional, Heyries, Laurent, additional, Reville, Marc, additional, Viron, Dominique, additional, Zerbib, Frank, additional, Claviere, Christophe, additional, Léostic, Didier, additional, Pouderoux, Philippe, additional, Moitry, Alain, additional, Hagège, Hervé, additional, Hugot, Jean-Pierre, additional, Humeau, Benoit, additional, Sabate, Jean-Marc, additional, Lederman, Emmanuel, additional, Lescut, Dominique, additional, Luneau, Fabrice, additional, Mesnard, Bruno, additional, Smadja, Lionel, additional, Steinberg, Michel, additional, Brun, Marc, additional, Macaigne, Gilles, additional, Marchal, Jean Luc, additional, Ollivier, Stéphane, additional, Ouvry, Dominique, additional, Perche, Jean Paul, additional, Rambaud, Serge, additional, Benamouzig, Robert, additional, Cazenave, Jean Louis, additional, Coffin, Jean-Charles, additional, Blazquez, Martine, additional, Lagneau, Marion, additional, Person, Bruno, additional, Wittersheim, Christian, additional, Napoleon, Bertrand, additional, Cemachovic, Israël, additional, Iglicki, Franck, additional, Howaizi, Mehran, additional, Leprince, Eric, additional, Leurent, Bruno, additional, Morin, Thierry, additional, Darsouni, Riad, additional, Attar, Alain, additional, Baron, Philippe, additional, Breton, Anne, additional, Gillion, Jean Marie, additional, Guemene, Jean-Marc, additional, Jouffre, Claude, additional, Moreau, Xavier, additional, Claude, Pierre, additional, Quinton, André, additional, Abitbol, Vered, additional, Brichard, Jean Michel, additional, Desaint, Benoit, additional, Bouygues, Martin, additional, Chatrenet, Philippe, additional, Salmeron, Marcelo, additional, Silvie, Jean, additional, Waldner, Bruno, additional, Emery, Yves, additional, Moraillon, Armand, additional, Kunkel, Daniel, additional, Dubois, Philippe, additional, Faure, Patrick, additional, L'Hirondel, Christian, additional, Labérenne, Jean-Eric, additional, Moreau, Pierre, additional, Pereira, Adelino, additional, Plihon, Genevieve, additional, Wolff, Thierry, additional, Ngo, Yann, additional, Boruchowicz, Arnaud, additional, Jost, Béatrice, additional, Gotlib, Jean Pierre, additional, Danne, Odile, additional, Raoux, Philippe, additional, Ramond-Bouhali, Marie-José, additional, Baetz, Andre, additional, Veyres, Bruno, additional, Chapoutot, Christian, additional, Le Dréau, Gérard, additional, Filippi, Jérôme, additional, Mudry, Jean, additional, Kalt, Philippe, additional, Minault, Sophie, additional, Bounin, Pierre-André, additional, Andréani, Tony, additional, Charneau, Jacky, additional, Reijasse, Didier, additional, Bolze, Jean-Louis, additional, Thaunat, Jean Luc, additional, Le Couteulx, Christian, additional, Maurage, Chantal, additional, Bader, Robert, additional, Codjovi, Philippe, additional, Migairou, Jean-Luc, additional, Morali, Alain, additional, Rey, Philippe, additional, Molard, Bruno Richard, additional, Petit, Richard, additional, Koch, Stéphane, additional, Cassan, Philippe, additional, Deschamps, Jean-Paul, additional, Caby, Christine Meicler, additional, Meurisse, Jean-Jacques, additional, Prades, Philippe, additional, Boulant, James, additional, Diacono, Michel, additional, Monsch, Jean-Marie, additional, Dupuy, J-François, additional, Bellaiche, Guy, additional, Guegan, Martine, additional, Comte, Jean-Marc, additional, Cayla, Jean-Michel, additional, Le Tallec, Francois, additional, Meurisse, Franck, additional, Desurmont, Philippe, additional, Roget, Laurent, additional, Bouyssou, Philippe, additional, Le Gall, Bruno, additional, Bloch, Francis, additional, Larvol, Loic, additional, Jullien, Monique, additional, Moreau, Jacques, additional, Rebouissoux, Laurent, additional, Decroix, Bruno, additional, Dib, Nina, additional, Dieterling, Paul, additional, Lenormand, Frédéric, additional, Lagier, Emmanuel, additional, Fallourd, Philippe, additional, Charpin, Serge, additional, Bertrand, Hugues, additional, Bommelaer, Gilles, additional, Battistelli, Daniel, additional, Delon, Bernard, additional, Dentant, Lionel, additional, Dorval, Etienne, additional, Dumortier, Jérôme, additional, Gaye-Bareyt, Eric, additional, Gerosa, Yves, additional, Guez, Chantal, additional, Mornet, Martine, additional, Benfredj, Paul, additional, Piperaud, René, additional, Stremsdoerfer, Noel, additional, Verdier, Eric, additional, Grinholtz, Alain, additional, Barjonet, Georges, additional, See, Antoine, additional, Arotçarena, Ramuntxo, additional, Baudet, Anne, additional, Broyer, Joel, additional, Charachon, Antoine, additional, Blondon, Hugues, additional, Mouton, Pascal, additional, Claudez, Hubert, additional, Labat-Labourdette, Jacques, additional, Haëm, Jacques, additional, Estable, Patrick, additional, Levy, Patrick, additional, Rosenbaum, Alain, additional, Balavoine, Yvon, additional, Blanchi, Alain, additional, Coutarel, Pierre, additional, Delaperriere, Nadege, additional, Dervichian, Michel, additional, Marois, Francis, additional, Seroka, Jacques, additional, Michaud, Laurent, additional, Leroy, Olivier, additional, Meyran, Emmanuel, additional, Poilroux, Bernard, additional, Tensaouti, Abdallah, additional, Paupard, Thierry, additional, Agard, Dominique, additional, Beaulieu, Sandrine, additional, Benfiguig, Kader, additional, Capony, Patrice, additional, Cottereau, Jean, additional, Desreumaux, Pierre, additional, Dramard, Jean-Michel, additional, Duché, Mathieu, additional, Mamou, Patrick, additional, Etienney, Isabelle, additional, D'Abrigeon, Gilles, additional, Godeberge, Béatrice, additional, Tucat, Gilbert, additional, Puech, Jean, additional, Roger, Jean, additional, Lapalus, Marie-George, additional, Bauret, Paul, additional, Houcke, Philippe, additional, Pornin, Béatrice, additional, Champigneulle, Bruno, additional, Cuissard, Laurent, additional, David, Xavier-Richard, additional, Lombard, Frédéric, additional, Granveau, Antoine, additional, Hamon, Jean-François, additional, Ink, Olivier, additional, Blondel, Fabienne, additional, Namias, Alain, additional, Pillon, Didier, additional, Reignier, Antoine, additional, Tordjman, Gilles, additional, Christidis, Christos, additional, Zirabe, Simon, additional, Audebert, Michel, additional, Bion, Eric, additional, Bourgeaux, Claude, additional, Poupardin, Cécile, additional, Deplaix, Philippe, additional, Fratini, Gérard, additional, Garnier, Thierry, additional, Desseaux, Gerard, additional, Magois, Hervé, additional, Lochum, Sylvain, additional, Vergier, Jean-Francois, additional, Texereau, Patrick, additional, Rat, Christel, additional, Uzzan, Francoise, additional, Vidal, Alain, additional, Vinante, Nadia, additional, Watrin, Bernard, additional, Wurtz-Huckert, Cécile, additional, Barre, Bruno, additional, Ferbus, Dominique Chaslin, additional, Contou, Jean-François, additional, Coupier, Dominique, additional, David, Benoit, additional, Gargot, Dany, additional, Huc, Denis, additional, Barraya, Remy, additional, Faroux, Roger, additional, Fourgeaud, Jean-Luc, additional, Grimprel, Hubert, additional, Auroux, Jean, additional, Rey, Jean-François, additional, Arnoux, Jean Pierre, additional, Lentini, Franck, additional, Tardy, Ludovic, additional, Mouterde, Olivier, additional, Spyckerelle, Claire, additional, Vacherot, Bruno, additional, Weissman, Alain, additional, Alpérine, Michel, additional, Le Sidaner, Anne, additional, Bonnet-Eymard, Pierre-Olivier, additional, Colson, Jean Louis, additional, Pellet, Daniel, additional, Deltombe, Bernard, additional, Edouard, André, additional, Maechel, Henri, additional, Jaillet, Jean-Claude, additional, Genes, Julien, additional, Leveque, Anne-Marie, additional, Lucidarme, Damien, additional, Maignan, Philippe, additional, Gehrke, Nathalie Mallier, additional, Sanchez, Jérôme, additional, Tusseau, Frank, additional, Casteur, Alban, additional, Bottlaender, Jacques, additional, Constantini, Denis, additional, Coton, Thierry, additional, Even, Philippe, additional, Druart, Francois, additional, Riot, François, additional, Gauchet, Jean-Michel, additional, Hecquet, Geneviève, additional, Henry, Gerard, additional, Hochain, Patrick, additional, Arpurt, Jean Pierre, additional, Medini, Abdelkrim, additional, Dartois-Hoguin, Michele, additional, Moindrot, Henri, additional, Emery, Philippe, additional, Periac, Pierre, additional, Prunier, Annie, additional, Renkes, Pascal, additional, Tawil-Longreen, Christine, additional, Vincent, Edmond, additional, Vitte, René-Louis, additional, Loeb, Christian, additional, Carwana, Alain, additional, Barbereau, Didier, additional, Bohon, Philippe, additional, Corrieri-Baizeau, Céline, additional, Sahy, Daniel, additional, Derreveaux, Philippe, additional, David, Dominique, additional, Desbazeille, François, additional, Fontenelle, Patrick, additional, Slama, Jean Luc, additional, Le Mercier, Yvon, additional, Certin, Michel, additional, Reig, Jean Jacques, additional, Rosa, Isabelle, additional, Helbert, Thierry, additional, Tounian, Patrick, additional, Turner, Luc, additional, Perot, Valéry, additional, Aillet, Luc, additional, Pauwels, Arnaud, additional, Barré, Philippe, additional, Nury, Bernard, additional, Cazalbou, Claude, additional, Devulder, Franck, additional, Durget, Alain, additional, Dubroca, Jeanne, additional, Gaudy, Daniele, additional, Greff, Michel, additional, Jacques, Christian, additional, Lafarge, Jocelyne, additional, Kezachian, Gilles, additional, Le Gall, Ronan, additional, Pariente, Alex, additional, Pinault, Tiphaine, additional, Bismuth, Michaël, additional, Boyer-Darrigrand, Nathalie, additional, Bretagnolle, Philippe, additional, Carpentier, Stephane, additional, Cholet, Franck, additional, Theodore, Christian, additional, Combes, Rémi, additional, Combet, Francois, additional, Delanoe, Christophe, additional, De Montigny, Stéphanie, additional, Soudan, Denis, additional, Fourdan, Olivier, additional, Minier, Gilles, additional, Languepin, Jeanne, additional, Roche, Jean, additional, Ginies, Jean-Louis, additional, Nouel, Olivier, additional, Petitgars, Philippe, additional, Robin, Edith, additional, Hamm, Romain, additional, Roques, Jean François, additional, Roussin-Bretagne, Sylvie, additional, Sénéjoux, Agnès, additional, Muron, Sophie, additional, Bardoux, Nicolas, additional, Berthelemy, Philippe, additional, Madonia, Patrick, additional, Carles, Bertrand, additional, Reynier, Catherine, additional, Cuillerier, Emmanuel, additional, Dadamessi, Innocenti, additional, Danis, Jacques, additional, Debenes, Bernard, additional, Dubuc-Rey, Nathalie, additional, Lesur, Gilles, additional, Jouet, Pauline, additional, Lenaerts, Catherine, additional, Garret, Marc, additional, Mineur, Alexandra, additional, Chabry, Bernard, additional, Pigot, Francois, additional, Rossi, Valérie, additional, Tennenbaum, Ruth, additional, Salloum, Julien, additional, Slaoui, Maurice Hakim, additional, Mathieu, Stéphane, additional, Papapietro, Valérie, additional, Viola, Sheila, additional, Bezet, Alexis, additional, Altman, Claude, additional, Audan, Alain, additional, Calabet, Jean, additional, Masliah, Claude, additional, Fayemendy, Laurent, additional, Duruy, Marc, additional, Gauffeny, Benoit, additional, Helie, Ludovic, additional, Imani, Kamran, additional, Janin-Manificat, Raoul, additional, Galmiche, Jean-Paul, additional, Kerlirzin, Anne, additional, Bedenne, Laurent, additional, Locher, Christophe, additional, Michaudel, Gilles, additional, Missonnier, Gilles, additional, Rinaldi-Dovio, Michel, additional, Rouillon, Jean-Michel, additional, Ecuer, Stéphane, additional, Patenotte, Arnaud, additional, Bronstein, Jean Ariel, additional, Baty, Vincent, additional, Bougnol, Michel, additional, Bourbon, Pierre, additional, Cerbelaud, Philippe, additional, Chavaillon, Annick, additional, Boiffin, Franck, additional, Dubern, Béatrice, additional, De Laguierce, Isabelle Duval, additional, Greco, Fernand, additional, Bouhot, Florence, additional, Godeberge, Philippe, additional, Grandmaison, Brigitte, additional, Gros, Pascal, additional, Targues, Guy, additional, Corallo, Jacques, additional, Boutin, Jean, additional, Guillan, Jacques, additional, Barbieux, Jean Pierre, additional, Lariviere, Isabelle Loury, additional, Le Genissel, Henri, additional, Leroi, Henri, additional, Bellaiche, Marc, additional, Elie-Legrand, Marie-Claire, additional, Dapoigny, Michel, additional, Denoyel, Philippe, additional, Pienkowski, Patrice, additional, Pouche, Philippe, additional, Saurfelt, Marc Michel, additional, Thorel, Jean Marie, additional, Piche, Thierry, additional, Travers, Bruno, additional, Tuvignon, Patrick, additional, Zalcberg, Marc, additional, Boulay, Guy, additional, Zamora, Christophe, additional, Samama, Joelle, additional, Ricotie, Etienne, additional, De Fleury, Patrice, additional, Maille, Francois, additional, Mougenel, Jean Louis, additional, Gonot, Olivier, additional, Menat, Jean Philippe, additional, Kaassis, Mehdi, additional, Lang, Francoise, additional, Abramowitz, Laurent, additional, Ganne, Nathalie, additional, Pecriaux, Olivier, additional, Seyrig, Jacques-Arnaud, additional, Sobhani, Iradj, additional, Parmentier, Thierry, additional, Van Nieuwenhuyse, Antoine, additional, Weber, Francois-Xavier, additional, Glibert, André, additional, Bineau, Catherine, additional, Canet, Bernard, additional, Collin, Catherine, additional, Cordet, Frederic, additional, Parlier, David David, additional, Carre, Dominique, additional, Peytier, Annie, additional, Fein, Francine, additional, Barouk, Jerome, additional, Dewannieux, Jacques, additional, Hartwig, Johannes, additional, Jouve, Jean-Louis, additional, Laplane, Bertrand, additional, Lascar, Gilles, additional, Legrand, Christophe, additional, Le Marchand, Pierre, additional, Liebaert, Marie Pierre, additional, Terdiman-Pire, Michele, additional, Abdelli, Naceur, additional, Neveu, Dominique, additional, De La Lande, Philippe, additional, De Saint Louvent, Patrick, additional, Pelatan, Cécile, additional, Petit, Agnès, additional, Richecoeur, Martial, additional, Texier, Frederic, additional, Cazals, Jean Brice, additional, Tissot, Bertrand, additional, Mourrut, Christian, additional, Doubremelle, Marie, additional, Foltz, Marc, additional, Gautier-Jubé, Florence, additional, Martin, Jacques, additional, Khouri, Elie, additional, Lons, Thierry, additional, Carlier-Bandu, Martine, additional, Monnin, Jean-Luc, additional, Roche, Hervé, additional, Willemin, Bernard, additional, Houard, Xavier, additional, Fatisse, Abdelaziz, additional, Algard, Michèle, additional, Arab, Kamel, additional, Borel, Isabelle, additional, Lagarrigue, Cécile, additional, Chryssostalis, Ariane, additional, Boutroux, Dominique, additional, Dupuychaffray, Jean-Pierre, additional, Khaddari, Saïd, additional, Mion, François, additional, Puy-Montbrun, Thierry, additional, Girardet, Jean-Philippe, additional, Gury, Bruno, additional, Landau, Alain, additional, Le Bihan, Monique, additional, Nieuviarts, Sandrine, additional, Ollivry, Jean, additional, Le Bourgeois, Philippe, additional, Piquet, Marie-Astrid, additional, Escartin, Michel -Pierre, additional, Systchenko, Remi, additional, Venezia, Franck, additional, Wantiez, Michel, additional, Lesage, Xavier, additional, Zrihen, Elie, additional, Aygalenq, Philippe, additional, Dieumegard, Barbara, additional, Savarieau, Bernard, additional, Bulois, Philippe, additional, Cattan, Stéphane, additional, Diez, Jean-Lucien, additional, Fauchot, Olivier, additional, Durous, Eric, additional, Gazut, Valérie, additional, Guilleminet, Christian, additional, Bories, Jean-Marc, additional, Le Floch, Isabelle Joly, additional, Vove, Jean-Paul, additional, Lelouch, Stéphane, additional, Lévy, Philippe, additional, Lhopital, François, additional, Marcato, Norma, additional, Mozer-Bernardeau, Marianne, additional, Nousbaum, Jean-Baptiste, additional, Cattan, Philippe, additional, Plane, Alain, additional, Raymond, Jean-Michel, additional, Roseau, Gilles, additional, Rozental, Gerald, additional, Boustière, Christian, additional, Bonny, Corinne, additional, Cordier-Collet, Mariepierre, additional, Courat, Laurent, additional, Croguennec, Bernard, additional, Tardy, Karine Delaunay-, additional, Labarriere, Damien, additional, Geagea, Edmond, additional, Gottrand, Frédéric, additional, Gelsi, Eve, additional, Thiefin, Gerard, additional, Wohlschies, Eric, additional, Miguet, Mathieu, additional, Ponsot, Philippe, additional, Suzanne, Jean, additional, Teste, Yves, additional, Dupont Gossart, Anne-Claire, additional, Baroni, Jean-Luc, additional, Benchaa, Benabdallah, additional, Blanc, Georges, additional, Maroy, Bernard, additional, Bonjean, Philippe, additional, Brézault, Catherine, additional, Bridoux-Henno, Laure, additional, Chayette, Claude, additional, Auby, Dominique, additional, Fiorucci, Robert, additional, Galindo, Georges, additional, Hubert, Gilles, additional, Bonneau, Gilles, additional, Marinier, Evelyne, additional, Pouteau, Michele, additional, Alamdari, Afchine, additional, Delbende, Bruno, additional, Chamouard, Patrick, additional, D'Abravanel, Pascale, additional, Dall'Osto, Hélène, additional, Hervé, Sophie, additional, Lefebvre, Jean, additional, Levoir, Damien, additional, Lillo, Philippe, additional, Rouch, Michel, additional, Mathonnet, Muriel, additional, De Lustrac, Mercédes, additional, Ramond, François-Jean, additional, Roupret, Bernard, additional, and Soupison, Alain, additional

Published
2018
Full Text
View/download PDF

248. 600 - Endoscopy Based Therapeutic Management in Postoperative Recurrent Crohn's Disease: Results of a Multi-Center Retrospective Study

Author

Rivière, Pauline, primary, Vermeire, Severine, additional, Irles-Depe, Marie, additional, Van Assche, Gert A., additional, Rutgeerts, Paul, additional, van Overstraeten, Anthony de Buck, additional, Denost, Quentin, additional, Wolthuis, Albert, additional, D'Hoore, Andre, additional, Laharie, David, additional, and Ferrante, Marc, additional

Published
2018
Full Text
View/download PDF

249. Mo1841 - Infliximab Exposure Predicts Superior Endoscopic Outcomes in Patients with Active Crohn's Disease: Pharmacokineticpharmacodynamic Analysis of Tailorix

Author

Dreesen, Erwin, primary, D'Haens, Geert R., additional, Baert, Filip J., additional, Pariente, Benjamin, additional, Bouhnik, Yoram, additional, Van Der Woude, Christien Janneke, additional, Moreau, Jacques, additional, Laharie, David, additional, Vermeire, Severine, additional, and Gils, Ann, additional

Published
2018
Full Text
View/download PDF

250. Mo1785 - Long-Term Outcome of Crohn's Disease Complicated by Upper Gastrointestinal Stricture: A Getaid Cohort Study

Author

Lambin, Thomas, primary, Amiot, Aurélien, additional, Gornet, Jean-Marc, additional, Seksik, Philippe, additional, Laharie, David, additional, Louis, Edouard, additional, Gilletta, Cyrielle, additional, Filippi, Jerome, additional, Fumery, Mathurin, additional, Cadiot, Guillaume, additional, de Chambrun, Guillaume Pineton, additional, Nahon, Stephane, additional, Serrero, Mélanie, additional, Coffin, Benoit, additional, Plastaras, Laurianne, additional, Viennot, Stephanie, additional, Dib, Nina, additional, Peyrin-Biroulet, Laurent, additional, and Pariente, Benjamin, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results